And this isn't even the most optimal formulation. They said they were looking at foam, in the conference call. That should get better coverage and be even more effective.

Plus, note that they are talking about the entire spectrum of IBD in this.

Just think what that market would be worth. And also look at the list of side effects of the current medications -- awful. Brilacidin -- no demonstrably bad side effects.